KROS - Keros Therapeutics, Inc.
IEX Last Trade
16.775
0.105 0.626%
Share volume: 28,712
Last Updated: Thu 26 Dec 2024 08:30:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$16.67
0.11
0.63%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-2.39%
1 Month
-70.88%
3 Months
-70.62%
6 Months
-63.32%
1 Year
-58.47%
2 Year
-64.21%
Key data
Stock price
$16.78
DAY RANGE
$16.30 - $16.74
52 WEEK RANGE
$17.08 - $73.00
52 WEEK CHANGE
-$59.29
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Jasbir S. Seehra
Region: US
Website: kerostx.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: kerostx.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Keros Therapeutics, Inc. focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia.
Recent news